This article is a correction to:
Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis
Fabricio A. Pamplona
Lorenzo Rolim da Silva
Ana Carolina Coan- 1Entourage Phytolab, São Paulo, Brazil
- 2Bedrocan Brasil, São Paulo, Brazil
- 3UNICAMP, Campinas, Brazil
A Corrigendum on
Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis
by Pamplona, F. A., da Silva, L. R., and Coan, A. C. (2018). Front. Neurol. 9:759. doi: 10.3389/fneur.2018.00759
In the original article, there was a mistake in Table 2 as published. The total number of one reference was wrongly included in the calculation of the endpoint efficacy over 70%. Where it reads 83/430, it should be 83/311, therefore 27% (instead of 19%). The corrected Table 2 appears below.
TABLE 2
Table 2. Efficacy of treatments in the reduction of convulsive seizures (heterogeneous population).
In the original article, there was a mistake in Table 4 as published. Data from one reference was missing in the calculation of the endpoints mild AE and severe AE. Where it reads 285/663, it should be 308/663, therefore 46% (instead of 43%). Where it reads 64/487, it should be 64/483. The corrected Table 4 appears below.
TABLE 4
Table 4. Negative secondary effects of treatment with CBD-rich Cannabis extracts and purified CBD described as secondary endpoints in the clinical studies.
In the original article, due to the errors in Tables 2, 4 mentioned above, corrections have been made to the Abstract as well as the Results, paragraphs one, two, three and five:
- “81/223, 36%” changed to “81/175, 46%” in Abstract and Results, paragraph one.
- “p = 0.56” changed to “p = 0.52” in Abstract and Results, paragraph two.
- “97/255, 38%” changed to “122/330, 37%” in Abstract and Results, paragraph two.
- “6.1 mg/kg/day” changed to “6.0 mg/kg/day” in Abstract and Results, paragraph two.
- “27.1 mg/kg/day” changed to “25.3 mg/kg/day” in Abstract and Results, paragraph two.
- “(109/285 vs. 291/346, p < 0.0001) and severe (23/285 vs. 77/346, p < 0.0001)” changed to “(158/216, 76% vs. 148/447, 33%, p < 0.001) and severe (41/155, 26% vs. 23/328, 7%, p < 0.0001)” in Abstract and Results, paragraph five.
- “17.7 mg/kg/day” changed to “15.0 mg/kg/day” in Results, paragraph two.
- “18%” changed to “27%” in Results, paragraph three.
- “83/430” changed to “83/311” in Results, paragraph three.
- “(Table 4)” changed to reference “(11)” in Results, paragraph five.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: cannabinoids, cannabidiol (CBD), epilepsy, meta-analysis, refractory epilepsy, phytotherapy
Citation: Pamplona FA, da Silva LR and Coan AC (2019) Corrigendum: Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Front. Neurol. 9:1050. doi: 10.3389/fneur.2018.01050
Received: 02 November 2018; Accepted: 20 November 2018;
Published: 10 January 2019.
Edited and reviewed by: Richard Lowell Bell, Indiana University, United States
Copyright © 2019 Pamplona, da Silva and Coan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fabricio A. Pamplona, ZmFicmljaW9wYW1wbG9uYUBnbWFpbC5jb20=